News & Updates
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it received acknowledgement by the Therapeutic Goods Administration (TGA) in Australia to conduct a Phase 1 clinical study of REVTx‑99…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced a multi-year commitment to decreasing breast cancer screening disparities for Black women. The program is in partnership with the Black Women’s Health Imperative (BWHI), the only nonprofit organization created by Black…
Read More
Excerpt from the Article: UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for SARS-CoV-2, the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals Companies of Johnson & Johnson, the trial will recruit up to 60,000 participants at sites in the…
Read More
Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled “COVID-19 associated…
Read More
Excerpt from the Press Release: WAKEFIELD, MA – October 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that earlier this week the Company submitted a pre-IND meeting request to the FDA in advance of a planned study of Brilacidin, a defensin-mimetic drug candidate, for the treatment of…
Read More
Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–Javelin Biotech (“Javelin”) today announces a three-year collaboration with Pfizer Inc. (NYSE: PFE) to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules. The ADME platform will integrate a microphysiological system (MPS), commonly referred to…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–COVISTAT Inc. and its parent company Ensysce, received IND allowance and today initiated a Phase 1 clinical trial of oral nafamostat in healthy volunteers. Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysce’s opioid overdose protection platform, is being developed as an oral treatment for COVID-19. The…
Read More
Excerpt from the Press Release: NEWTON, Mass. and MILAN, Sept. 24, 2020 /PRNewswire/ — InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation (MR), announced today the successful First-in-Human implantation of its proprietary Saturn Transcatheter Mitral Valve along with excellent results at the 30-day follow-up for the…
Read More
Excerpt from the Article: Researchers have reported hopeful results from an early clinical trial of a potential coronavirus vaccine developed by a team from from Beth Israel Deaconess Medical Center and Johnson & Johnson. The company announced earlier this week it has moved forward to field test what could be a the first single-shot vaccine for the virus in…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?